pipeline | autoimmune/inflammation | oncology
We expect to file our first IND for autoimmune/inflammatory disease in Q4-2018. Our first IND for oncology in planned for 2019.
Alpine Immune Sciences Announces Preclinical Data Demonstrating ALPN-202 Eliminates Tumors and Creates Persistent T… twitter.com/i/web/status/98630…
April 17, 2018 6:04 pm
Our #AACR18 poster features our lead program for #cancer #immunotherapy ALPN-202 is a dual PD-L1/CTLA-4 antagonist… twitter.com/i/web/status/98343…
April 9, 2018 8:01 pm
© 2018 Alpine Immune Sciences. All Rights Reserved, Alpine Immune Sciences Inc.